登革佳®——一种有前景的登革热疫苗；它能推荐给无免疫力的旅行者吗？

Qdenga® - A promising dengue fever vaccine; can it be recommended to non-immune travelers?

作者信息

Angelin Martin, Sjölin Jan, Kahn Fredrik, Ljunghill Hedberg Anna, Rosdahl Anja, Skorup Paul, Werner Simon, Woxenius Susanne, Askling Helena H

机构信息

Department of Clinical Microbiology, Infectious Diseases, Umeå University, Sweden.

Department of Medical Sciences, Section of Infectious Diseases, Uppsala University, Sweden.

出版信息

Travel Med Infect Dis. 2023 Jul-Aug;54:102598. doi: 10.1016/j.tmaid.2023.102598. Epub 2023 Jun 2.

DOI:10.1016/j.tmaid.2023.102598

PMID:37271201

Abstract

Qdenga® has been approved by the European Medicines Agency (EMA) for individuals > 4 years of age and for use according to national recommendations. The vaccine shows high efficacy against virologically confirmed dengue and severe dengue in clinical studies on 4-16-year old's living in endemic areas. For individuals 16-60 years old only serological data exists and there is no data for individuals > 60 years. Its use as a travel vaccine is still unclear. We present the studies behind the approval and the recommendations for travelers as issued by the Swedish Society for Infectious Diseases Physicians.

摘要

Qdenga®已获得欧洲药品管理局（EMA）批准，适用于4岁以上人群，并可根据国家建议使用。在针对生活在流行地区的4至16岁儿童的临床研究中，该疫苗对病毒学确诊的登革热和重症登革热显示出高疗效。对于16至60岁的个体，仅有血清学数据，且没有60岁以上个体的数据。其作为旅行疫苗的用途仍不明确。我们介绍了该疫苗获批背后的研究以及瑞典传染病医师协会发布的旅行者建议。